
Hemant Desai
Examiner (ID: 19091)
| Most Active Art Unit | 3721 |
| Art Unit(s) | 3731, 3721 |
| Total Applications | 1094 |
| Issued Applications | 787 |
| Pending Applications | 41 |
| Abandoned Applications | 266 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17111751
[patent_doc_number] => 20210292348
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => ANTIVIRAL COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/178115
[patent_app_country] => US
[patent_app_date] => 2021-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60632
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17178115
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/178115 | Antiviral compounds | Feb 16, 2021 | Issued |
Array
(
[id] => 16854882
[patent_doc_number] => 20210155627
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => KINASE INHIBITORS AND RELATED METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/165048
[patent_app_country] => US
[patent_app_date] => 2021-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18389
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165048
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/165048 | Kinase inhibitors and related methods of use | Feb 1, 2021 | Issued |
Array
(
[id] => 18225333
[patent_doc_number] => 20230064327
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => REDUCING SIDE EFFECTS OF NMDA ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/792208
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59015
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -174
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792208
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/792208 | REDUCING SIDE EFFECTS OF NMDA ANTAGONISTS | Jan 21, 2021 | Pending |
Array
(
[id] => 16837808
[patent_doc_number] => 20210145820
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/154312
[patent_app_country] => US
[patent_app_date] => 2021-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154312
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/154312 | Methods for the treatment of abnormal involuntary movement disorders | Jan 20, 2021 | Issued |
Array
(
[id] => 19701437
[patent_doc_number] => 12195446
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-14
[patent_title] => Heteroaryl compounds and their use as therapeutic drugs
[patent_app_type] => utility
[patent_app_number] => 17/138309
[patent_app_country] => US
[patent_app_date] => 2020-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35688
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 555
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17138309
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/138309 | Heteroaryl compounds and their use as therapeutic drugs | Dec 29, 2020 | Issued |
Array
(
[id] => 18148343
[patent_doc_number] => 20230022200
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => DRUG THAT PREVENTS DIALYSIS SHIFT OR RENAL DEATH
[patent_app_type] => utility
[patent_app_number] => 17/781778
[patent_app_country] => US
[patent_app_date] => 2020-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12481
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17781778
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/781778 | DRUG THAT PREVENTS DIALYSIS SHIFT OR RENAL DEATH | Dec 22, 2020 | Pending |
Array
(
[id] => 16930839
[patent_doc_number] => 20210196728
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => METHODS OF TREATING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) DYSFUNCTION
[patent_app_type] => utility
[patent_app_number] => 17/130580
[patent_app_country] => US
[patent_app_date] => 2020-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8390
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130580
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/130580 | Methods of treating cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction | Dec 21, 2020 | Issued |
Array
(
[id] => 16913870
[patent_doc_number] => 20210186962
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => METHODS OF SCHIZOPHRENIA TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/127867
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6995
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127867
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/127867 | METHODS OF SCHIZOPHRENIA TREATMENT | Dec 17, 2020 | Pending |
Array
(
[id] => 16822590
[patent_doc_number] => 20210137883
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => ANTI-NEOPLASTIC COMPOUNDS AND METHODS TARGETING QSOX1
[patent_app_type] => utility
[patent_app_number] => 17/124242
[patent_app_country] => US
[patent_app_date] => 2020-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2458
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17124242
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/124242 | ANTI-NEOPLASTIC COMPOUNDS AND METHODS TARGETING QSOX1 | Dec 15, 2020 | Abandoned |
Array
(
[id] => 17959997
[patent_doc_number] => 20220340577
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => GCN2 INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/122543
[patent_app_country] => US
[patent_app_date] => 2020-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 210581
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17122543
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/122543 | GCN2 INHIBITORS AND USES THEREOF | Dec 14, 2020 | Pending |
Array
(
[id] => 18123535
[patent_doc_number] => 20230009145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-12
[patent_title] => INHIBITION OF TMEM16A BY BENZBROMARONE OR NICLOSAMIDE FOR TREATING POLYCYSTIC KIDNEY DISEASE AND/OR POLYCYSTIC LIVER DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/782643
[patent_app_country] => US
[patent_app_date] => 2020-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8791
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782643
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782643 | INHIBITION OF TMEM16A BY BENZBROMARONE OR NICLOSAMIDE FOR TREATING POLYCYSTIC KIDNEY DISEASE AND/OR POLYCYSTIC LIVER DISEASE | Dec 8, 2020 | Pending |
Array
(
[id] => 17183775
[patent_doc_number] => 20210330660
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/114169
[patent_app_country] => US
[patent_app_date] => 2020-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3388
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17114169
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/114169 | FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS | Dec 6, 2020 | Abandoned |
Array
(
[id] => 17089730
[patent_doc_number] => 11117907
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-14
[patent_title] => Curcuminoid-inspired synthetic compounds as anti-tumor agents
[patent_app_type] => utility
[patent_app_number] => 17/112328
[patent_app_country] => US
[patent_app_date] => 2020-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 261
[patent_figures_cnt] => 282
[patent_no_of_words] => 40617
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17112328
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/112328 | Curcuminoid-inspired synthetic compounds as anti-tumor agents | Dec 3, 2020 | Issued |
Array
(
[id] => 18603377
[patent_doc_number] => 11744817
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-05
[patent_title] => High-dose statins for age-related macular degeneration
[patent_app_type] => utility
[patent_app_number] => 17/108065
[patent_app_country] => US
[patent_app_date] => 2020-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 7
[patent_no_of_words] => 9275
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17108065
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/108065 | High-dose statins for age-related macular degeneration | Nov 30, 2020 | Issued |
Array
(
[id] => 17168621
[patent_doc_number] => 20210322291
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => COMPOUNDS AND METHODS FOR REPELLING BLOOD-FEEDING ARTHROPODS AND DETERRING THEIR LANDING AND FEEDING
[patent_app_type] => utility
[patent_app_number] => 17/101286
[patent_app_country] => US
[patent_app_date] => 2020-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3453
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101286
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/101286 | COMPOUNDS AND METHODS FOR REPELLING BLOOD-FEEDING ARTHROPODS AND DETERRING THEIR LANDING AND FEEDING | Nov 22, 2020 | Abandoned |
Array
(
[id] => 17065734
[patent_doc_number] => 20210267949
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS
[patent_app_type] => utility
[patent_app_number] => 16/950973
[patent_app_country] => US
[patent_app_date] => 2020-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16140
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950973
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/950973 | Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils | Nov 17, 2020 | Issued |
Array
(
[id] => 18363765
[patent_doc_number] => 20230145356
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => USE OF FAK INHIBITOR IN PREPARATION OF DRUG FOR TREATING TUMORS HAVING NRAS MUTATION
[patent_app_type] => utility
[patent_app_number] => 17/777769
[patent_app_country] => US
[patent_app_date] => 2020-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7152
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777769
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/777769 | USE OF FAK INHIBITOR IN PREPARATION OF DRUG FOR TREATING TUMORS HAVING NRAS MUTATION | Nov 16, 2020 | Pending |
Array
(
[id] => 16837762
[patent_doc_number] => 20210145774
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => Treatment of alcoholic liver disease
[patent_app_type] => utility
[patent_app_number] => 17/096217
[patent_app_country] => US
[patent_app_date] => 2020-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4885
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096217
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/096217 | Treatment of alcoholic liver disease | Nov 11, 2020 | Abandoned |
Array
(
[id] => 18666200
[patent_doc_number] => 11773077
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-03
[patent_title] => Compounds containing carbon-carbon linker as GPR120 agonists
[patent_app_type] => utility
[patent_app_number] => 17/087144
[patent_app_country] => US
[patent_app_date] => 2020-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21302
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 307
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17087144
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/087144 | Compounds containing carbon-carbon linker as GPR120 agonists | Nov 1, 2020 | Issued |
Array
(
[id] => 18064402
[patent_doc_number] => 20220395489
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-15
[patent_title] => THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY BOWEL DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/771737
[patent_app_country] => US
[patent_app_date] => 2020-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38915
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771737
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/771737 | THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY BOWEL DISEASE | Oct 27, 2020 | Pending |